'Breakthrough results': Why this ASX healthcare share just exploded 160%

BCAL Diagnostics has developed a blood test to detect breast cancer that it says may be ready for commercialisation within a year.

| More on:
four excited doctors with their hands in the air

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX healthcare share BCAL Diagnostics Ltd (ASX: BDX) skyrocketed to a new 52-week high of 21 cents today after the company revealed some exciting news.

At its intraday high, the BCAL share price was up 162.5%.

The ASX healthcare share has since retreated to 14.5 cents, up 81%.

Let's take a look at the details of BCAL's announcement.

ASX healthcare share shoots the lights out

BCAL Diagnostics has developed a blood test to detect breast cancer, which it is now testing for efficacy.

The company said today it has now taken a major step toward commercialisation of its breast cancer diagnostic test.

In a statement, BCAL said it has received "breakthrough results" from a clinical study co-sponsored with United States company Precion Inc.

The analysis undertaken achieved sensitivity (ability to detect true positive samples) of 90% and a specificity (ability to detect true negative samples) of 85.5%.

The results replicated earlier studies conducted in Australia using a different mass spectrometry platform.

Commercial sales by second half of 2024

BCAL says the results enhance its confidence that the blood test will be ready for commercial sales in the second half of calendar 2024.

The test would be used in conjunction with mammograms.

The company said the results mean commercial labs around the world should be able to use blood samples from the BCAL test to detect cancer.

Bcal said this will expedite its access and penetration into existing and new global markets.

Executive Chair of BCAL Jayne Shaw said:

These results are a major step towards making our test broadly available to patients and clinicians.

We will continue to work closely with leading scientists and doctors as our science team further optimises the test to make it more cost-effective when it is launched as a patient friendly blood test for detecting breast cancer

BCAL is a relatively new ASX healthcare share, listed in 2021.

The company has a market capitalisation of $16.91 million.

BCAL will be hosting an investor webinar on 8 August to further update shareholders.

How are ASX healthcare shares faring in 2023?

ASX healthcare shares are considered defensive stocks in a volatile economy.

Defensive shares represent companies that can produce stable earnings in any economic conditions.

However, ASX 200 healthcare shares are underperforming the S&P/ASX 200 Index (ASX: XJO) in 2023.

The S&P/ASX 200 Health Care Index (ASX: XHJ) is down 0.073% while the broader ASX 200 is up 6.6%.

Should you invest $1,000 in Bcal Diagnostics right now?

Before you buy Bcal Diagnostics shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Bcal Diagnostics wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Healthcare Shares

Guess which ASX 200 stock is jumping 16% on big news

Let's find out what news is getting investors excited this afternoon.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX 300 stock crashing 18% today?

Investors are rushing to the exits. But why? Let's look into things.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are CSL shares at risk from the Trump tariffs?

How exposed are CSL shares to potential Trump medicinal tariffs?

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

What did CSL have to say at Macquarie's 2025 conference?

Does this business have a healthy growth outlook?

Read more »

smiling health care workers in a medical setting
Healthcare Shares

Sonic Healthcare shares are down more than 40% since 2021. Will its AI initiative be the catalyst for a turnaround?

Could AI spark a recovery for this ASX healthcare stock?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

Read more »